Improving Routes in API Manufacturing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Improving Routes in API Manufacturing
Catalytic routes to producing atorvastatin and sitagliptin are recent advancements.

Pharmaceutical Technology

WelChol is marketed by Genzyme Corporation's (Cambridge, MA) US marketing partner for the product, Daiichi Sankyo, Inc. (Parsippany, NJ).

WelChol is indicated for lowering low-density lipoprotein (LDL) cholesterol and was approved by FDA in May 2000. In December 2006, Daiichi Sanyko submitted a supplemental new drug application to the FDA for WelChol to improve glycemic control in patients with Type 2 diabetes mellitus. If approved, WelChol will be the first LDL cholesterol-lowering medication also indicated for improving glycemic control. The new indication for WelChol for treating Type 2 diabetes would potentially increase the volume requirements for colesevelam.

To meet current and projected demand, DSM is evaluating a potential new investment at its Linz facility, which would include the addition of new manufacturing equipment to increase the efficiency in the gel-cutting procedure and the reaction part of the colesevelam production unit.

In December 2006, DSM produced its millionth kilogram of colesevelam at the Linz facility. DSM optimized the manufacturing process for colesevelam and supplied the initial 25 kg for conducting the first human clinical trials to the innovator of the product, Geltex Pharmaceuticals, Inc., which was acquired by Genzyme in 2000. DSM has manufactured the API on a commercial scale since the drug's US marketing approval in 2000 and European approval in 2004.

In optimizing the manufacturing process for colesevelam, DSM had to overcome certain key challenges. Colesevelam is poly (allylamine hydrochloride), cross-linked with epichlorohydrin and alkylated with (6-bromohexyl) trimethylammonium bromide and 1-bromodecane.The main steps of the API synthesis are the cross-linking of poly (allylamine hydrochloride) and the alkylation of the cross-linked polymer.

Geltex first approached DSM with the project because it had difficulty producing the product on an industrial scale. Although the synthesis of the compound was not problematic, the material is a polymer hydrogel, and DSM had to design specialized equipment to cut the material. DSM engineer George Haubel worked with a team that designed the gel cutter and the specific reactors for polymer-suspension reactions.

DSM optimized the manufacturing process for colesevelam, which is carried out by cross-linkage, comminution, alkylation, washing with several washing steps between the individual stages, and drying in a fluid-bed dryer (4). Following polymerization, the cured crude gel is cut in a defined shape, washed with methanol batchwise in a static or stirred bed, followed by alkylation in methanol. The akylated gel is washed in methanol and sodium chloride in a static or stirred bed followed by washes of sodium chloride and final water washes with deionized water (4). Because of the adhesive quality of the gel, the material is dried in a fluid-bed dryer because it adheres to the surface of a cone dryer.

The particle size of the API is important for the clinical efficacy of the drug. Colesevelam is a non-systemic drug that is not absorbed into the bloodstream and does not pass through the liver and kidneys. It travels through the body to the intestines, where it binds to bile acids, which are then carried out of the body by the normal digestive process. Bile acids are made from cholesterol. The body needs to use LDL to make more bile acids. This process reduces the amount of bad cholesterol in the blood.

If the particle size of the API were too small, it would be absorbed by the body, and if too large, it would be retained in the system. Micronization of the API is performed by Powdersize, Inc. (Quakertown, PA).

Aptamer technology

An emerging area in API development is aptamers. Aptamers are single-stranded nucleic acids that form well-defined three-dimensional shapes, which allows them to bind to target molecules in a manner that is conceptually similar to antibodies, according to Archemix (Cambridge, MA), a company specializing in aptamer development. Unlike monoclonal antibodies, aptamers are chemically synthesized, rather than biologically expressed.

Archemix recently signed aptamer drug development pacts with Merck KGaA (Darmstadt, Germany), Takeda Pharmaceutical Company (Osaka, Japan), and Pfizer.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here